Page 128 - Drug Class Review
P. 128
Page 94 of 205
Drug Effectiveness Review Project
galantamine 73.2% 23.2% 14.3% 8.9% 12.5% 5.4% 7.1% 5.4% Open-label; only cognitive assessments were implemented by independent raters who were blinded to galantamine 8.9% 7.1%
donepezil 67.2% 15.6% 9.4% 4.7% 0.0% 6.3% 3.1% 1.6% Post randomization exclusions: NR Overall loss to follow-up: 6.7% Loss to follow-up differential high: No donepezil 4.7% 4.7%
ITT: Yes patient assignment;
NR Yes NR N/A
Final Report Update 1 Authors: Jones et al. Year: 2004 ADVERSE EVENTS: Overall adverse effects reported: Nausea • Diarrhea • Anorexia • Vomiting • Headache • UTI • Dizziness • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
